By Dean Seal
Kura Oncology has promoted an executive vice president to chief medical officer after Stephen Dale left the role to recover from personal health challenges.
The clinical-stage biopharmaceutical company said Monday that Mollie Leoni is joining the C-suite after serving as executive vice president of clinical development. She joined the company as a vice president in February 2020 and was promoted in July 2023.
Kura also said that Francis Burrows, who has led the company's translational research efforts for the past nine years, has been promoted to chief scientific officer.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 06, 2025 18:18 ET (23:18 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.